RBC Capital: 'KOL Sees Ascendis Pharma's (ASND) Commercial Momentum Continuing Steadily From Here'
Tweet Send to a Friend
RBC Capital analyst Luca Issi reiterated an Outperform rating and $225.00 price target on Ascendis Pharma (NASDAQ: ASND).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
